| Objective To evaluate the efficacy and safety of bisphosphonates for the treatment of osteoporosis patients with lumbar spinal fusion surgery using a meta-analysis system. Methods Publications from inception to January 2017 concerning bisphosphonates for the treatment of osteoporosis patients with lumbar spinal fusion surgery were retrieved through PubMed, ScienceDirect, Google Scholar, CNKI, VIP and Wanfang resource databases. Data analysis was performed using Stata 11.0 and the literatures that were finally included were analyzed systematically. Results Nine randomized controlled trials were included. The results of meta-analysis showed that there were significant differences between the bisphosphonates group and control group in the treatment of osteoporosis patients with lumbar spinal fusion surgery (P<0.01) for bone fusion (RR=1.138, 95% CI 1.064, 1.217), bone mineral density T-score (MD=0.038, 95% CI 0.025, 0.052), Oswestry Disability Index (MD=–4.36, 95% CI –6.372, –2.348), bone resorption biochemical marker CTX (MD=–0.401, 95% CI –0.511, –0.291) and visual analog scale (MD=0.940, 95% CI 0.548, 1.332). There were no significant differences in bone formation biochemical marker PINP (MD=–4.328, 95% CI –8.954, 0.298) and adverse reactions (RR=0.725，95% CI 0.420, 1.251) (P=0.067 and P=0.248). Conclusion There was no association between bisphosphonates treatment and nonunion of lumbar spinal bone, and safety is similar to that of the control group. In addition, it can effectively inhibit bone absorption, improve patients’ bone mass and degree of postoperative functional recovery. |